img

Global Quadrivalent Flu Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Quadrivalent Flu Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The global Quadrivalent Flu Vaccine market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Quadrivalent Flu Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Quadrivalent Flu Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Quadrivalent Flu Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Quadrivalent Flu Vaccine include Sanofi Pasteur, AstraZeneca, CSL, Abbott and GlaxoSmithKline, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Quadrivalent Flu Vaccine, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Quadrivalent Flu Vaccine by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Quadrivalent Flu Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Quadrivalent Flu Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
By Type
Intramuscular Injection
Nasal Spray
Intradermal Shot
By Application
Hospital
Clinic
Public Health Agency
Other
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Quadrivalent Flu Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Quadrivalent Flu Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Quadrivalent Flu Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Quadrivalent Flu Vaccine Definition
1.2 Market by Type
1.2.1 Global Quadrivalent Flu Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Intramuscular Injection
1.2.3 Nasal Spray
1.2.4 Intradermal Shot
1.3 Market Segment by Application
1.3.1 Global Quadrivalent Flu Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Public Health Agency
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Quadrivalent Flu Vaccine Sales
2.1 Global Quadrivalent Flu Vaccine Revenue Estimates and Forecasts 2018-2034
2.2 Global Quadrivalent Flu Vaccine Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Quadrivalent Flu Vaccine Revenue by Region
2.3.1 Global Quadrivalent Flu Vaccine Revenue by Region (2018-2024)
2.3.2 Global Quadrivalent Flu Vaccine Revenue by Region (2024-2034)
2.4 Global Quadrivalent Flu Vaccine Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Quadrivalent Flu Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Quadrivalent Flu Vaccine Sales Quantity by Region
2.6.1 Global Quadrivalent Flu Vaccine Sales Quantity by Region (2018-2024)
2.6.2 Global Quadrivalent Flu Vaccine Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Quadrivalent Flu Vaccine Sales Quantity by Manufacturers
3.1.1 Global Quadrivalent Flu Vaccine Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Quadrivalent Flu Vaccine Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Quadrivalent Flu Vaccine Sales in 2022
3.2 Global Quadrivalent Flu Vaccine Revenue by Manufacturers
3.2.1 Global Quadrivalent Flu Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Quadrivalent Flu Vaccine Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Quadrivalent Flu Vaccine Revenue in 2022
3.3 Global Quadrivalent Flu Vaccine Sales Price by Manufacturers
3.4 Global Key Players of Quadrivalent Flu Vaccine, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Quadrivalent Flu Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Quadrivalent Flu Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Quadrivalent Flu Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Quadrivalent Flu Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Quadrivalent Flu Vaccine Sales Quantity by Type
4.1.1 Global Quadrivalent Flu Vaccine Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Quadrivalent Flu Vaccine Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Quadrivalent Flu Vaccine Sales Quantity Market Share by Type (2018-2034)
4.2 Global Quadrivalent Flu Vaccine Revenue by Type
4.2.1 Global Quadrivalent Flu Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Quadrivalent Flu Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Quadrivalent Flu Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Quadrivalent Flu Vaccine Price by Type
4.3.1 Global Quadrivalent Flu Vaccine Price by Type (2018-2024)
4.3.2 Global Quadrivalent Flu Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Quadrivalent Flu Vaccine Sales Quantity by Application
5.1.1 Global Quadrivalent Flu Vaccine Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Quadrivalent Flu Vaccine Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Quadrivalent Flu Vaccine Sales Quantity Market Share by Application (2018-2034)
5.2 Global Quadrivalent Flu Vaccine Revenue by Application
5.2.1 Global Quadrivalent Flu Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Quadrivalent Flu Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Quadrivalent Flu Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Quadrivalent Flu Vaccine Price by Application
5.3.1 Global Quadrivalent Flu Vaccine Price by Application (2018-2024)
5.3.2 Global Quadrivalent Flu Vaccine Price Forecast by Application (2024-2034)
6 North America
6.1 North America Quadrivalent Flu Vaccine Sales by Company
6.1.1 North America Quadrivalent Flu Vaccine Revenue by Company (2018-2024)
6.1.2 North America Quadrivalent Flu Vaccine Sales Quantity by Company (2018-2024)
6.2 North America Quadrivalent Flu Vaccine Market Size by Type
6.2.1 North America Quadrivalent Flu Vaccine Sales Quantity by Type (2018-2034)
6.2.2 North America Quadrivalent Flu Vaccine Revenue by Type (2018-2034)
6.3 North America Quadrivalent Flu Vaccine Market Size by Application
6.3.1 North America Quadrivalent Flu Vaccine Sales Quantity by Application (2018-2034)
6.3.2 North America Quadrivalent Flu Vaccine Revenue by Application (2018-2034)
6.4 North America Quadrivalent Flu Vaccine Market Size by Country
6.4.1 North America Quadrivalent Flu Vaccine Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Quadrivalent Flu Vaccine Revenue by Country (2018-2034)
6.4.3 North America Quadrivalent Flu Vaccine Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Quadrivalent Flu Vaccine Sales by Company
7.1.1 Europe Quadrivalent Flu Vaccine Sales Quantity by Company (2018-2024)
7.1.2 Europe Quadrivalent Flu Vaccine Revenue by Company (2018-2024)
7.2 Europe Quadrivalent Flu Vaccine Market Size by Type
7.2.1 Europe Quadrivalent Flu Vaccine Sales Quantity by Type (2018-2034)
7.2.2 Europe Quadrivalent Flu Vaccine Revenue by Type (2018-2034)
7.3 Europe Quadrivalent Flu Vaccine Market Size by Application
7.3.1 Europe Quadrivalent Flu Vaccine Sales Quantity by Application (2018-2034)
7.3.2 Europe Quadrivalent Flu Vaccine Revenue by Application (2018-2034)
7.4 Europe Quadrivalent Flu Vaccine Market Size by Country
7.4.1 Europe Quadrivalent Flu Vaccine Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Quadrivalent Flu Vaccine Revenue by Country (2018-2034)
7.4.3 Europe Quadrivalent Flu Vaccine Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Quadrivalent Flu Vaccine Sales by Company
8.1.1 China Quadrivalent Flu Vaccine Sales Quantity by Company (2018-2024)
8.1.2 China Quadrivalent Flu Vaccine Revenue by Company (2018-2024)
8.2 China Quadrivalent Flu Vaccine Market Size by Type
8.2.1 China Quadrivalent Flu Vaccine Sales Quantity by Type (2018-2034)
8.2.2 China Quadrivalent Flu Vaccine Revenue by Type (2018-2034)
8.3 China Quadrivalent Flu Vaccine Market Size by Application
8.3.1 China Quadrivalent Flu Vaccine Sales Quantity by Application (2018-2034)
8.3.2 China Quadrivalent Flu Vaccine Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Quadrivalent Flu Vaccine Sales by Company
9.1.1 APAC Quadrivalent Flu Vaccine Sales Quantity by Company (2018-2024)
9.1.2 APAC Quadrivalent Flu Vaccine Revenue by Company (2018-2024)
9.2 APAC Quadrivalent Flu Vaccine Market Size by Type
9.2.1 APAC Quadrivalent Flu Vaccine Sales Quantity by Type (2018-2034)
9.2.2 APAC Quadrivalent Flu Vaccine Revenue by Type (2018-2034)
9.3 APAC Quadrivalent Flu Vaccine Market Size by Application
9.3.1 APAC Quadrivalent Flu Vaccine Sales Quantity by Application (2018-2034)
9.3.2 APAC Quadrivalent Flu Vaccine Revenue by Application (2018-2034)
9.4 APAC Quadrivalent Flu Vaccine Market Size by Region
9.4.1 APAC Quadrivalent Flu Vaccine Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Quadrivalent Flu Vaccine Revenue by Region (2018-2034)
9.4.3 APAC Quadrivalent Flu Vaccine Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales by Company
10.1.1 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Market Size by Type
10.2.1 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Market Size by Application
10.3.1 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Market Size by Country
10.4.1 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Sanofi Pasteur
11.1.1 Sanofi Pasteur Company Information
11.1.2 Sanofi Pasteur Overview
11.1.3 Sanofi Pasteur Quadrivalent Flu Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Sanofi Pasteur Quadrivalent Flu Vaccine Products and Services
11.1.5 Sanofi Pasteur Quadrivalent Flu Vaccine SWOT Analysis
11.1.6 Sanofi Pasteur Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Quadrivalent Flu Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 AstraZeneca Quadrivalent Flu Vaccine Products and Services
11.2.5 AstraZeneca Quadrivalent Flu Vaccine SWOT Analysis
11.2.6 AstraZeneca Recent Developments
11.3 CSL
11.3.1 CSL Company Information
11.3.2 CSL Overview
11.3.3 CSL Quadrivalent Flu Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 CSL Quadrivalent Flu Vaccine Products and Services
11.3.5 CSL Quadrivalent Flu Vaccine SWOT Analysis
11.3.6 CSL Recent Developments
11.4 Abbott
11.4.1 Abbott Company Information
11.4.2 Abbott Overview
11.4.3 Abbott Quadrivalent Flu Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Abbott Quadrivalent Flu Vaccine Products and Services
11.4.5 Abbott Quadrivalent Flu Vaccine SWOT Analysis
11.4.6 Abbott Recent Developments
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Information
11.5.2 GlaxoSmithKline Overview
11.5.3 GlaxoSmithKline Quadrivalent Flu Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 GlaxoSmithKline Quadrivalent Flu Vaccine Products and Services
11.5.5 GlaxoSmithKline Quadrivalent Flu Vaccine SWOT Analysis
11.5.6 GlaxoSmithKline Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Quadrivalent Flu Vaccine Value Chain Analysis
12.2 Quadrivalent Flu Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Quadrivalent Flu Vaccine Production Mode & Process
12.4 Quadrivalent Flu Vaccine Sales and Marketing
12.4.1 Quadrivalent Flu Vaccine Sales Channels
12.4.2 Quadrivalent Flu Vaccine Distributors
12.5 Quadrivalent Flu Vaccine Customers
13 Market Dynamics
13.1 Quadrivalent Flu Vaccine Industry Trends
13.2 Quadrivalent Flu Vaccine Market Drivers
13.3 Quadrivalent Flu Vaccine Market Challenges
13.4 Quadrivalent Flu Vaccine Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Quadrivalent Flu Vaccine Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Intramuscular Injection
Table 3. Major Manufacturers of Nasal Spray
Table 4. Major Manufacturers of Intradermal Shot
Table 5. Global Quadrivalent Flu Vaccine Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Quadrivalent Flu Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Quadrivalent Flu Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Quadrivalent Flu Vaccine Revenue Market Share by Region (2018-2024)
Table 9. Global Quadrivalent Flu Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Quadrivalent Flu Vaccine Revenue Market Share by Region (2024-2034)
Table 11. Global Quadrivalent Flu Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Doses)
Table 12. Global Quadrivalent Flu Vaccine Sales by Region (2018-2024) & (K Doses)
Table 13. Global Quadrivalent Flu Vaccine Sales Market Share by Region (2018-2024)
Table 14. Global Quadrivalent Flu Vaccine Sales by Region (2024-2034) & (K Doses)
Table 15. Global Quadrivalent Flu Vaccine Sales Market Share by Region (2024-2034)
Table 16. Global Quadrivalent Flu Vaccine Sales Quantity by Manufacturers (2018-2024) & (K Doses)
Table 17. Global Quadrivalent Flu Vaccine Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global Quadrivalent Flu Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Quadrivalent Flu Vaccine Revenue Share by Manufacturers (2018-2024)
Table 20. Global Quadrivalent Flu Vaccine Price by Manufacturers 2018-2024 (USD/Dose)
Table 21. Global Key Players of Quadrivalent Flu Vaccine, Industry Ranking, 2021 VS 2022
Table 22. Global Quadrivalent Flu Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Quadrivalent Flu Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Quadrivalent Flu Vaccine as of 2022)
Table 24. Global Key Manufacturers of Quadrivalent Flu Vaccine, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Quadrivalent Flu Vaccine, Product Offered and Application
Table 26. Global Key Manufacturers of Quadrivalent Flu Vaccine, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Quadrivalent Flu Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 29. Global Quadrivalent Flu Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 30. Global Quadrivalent Flu Vaccine Sales Quantity Share by Type (2018-2024)
Table 31. Global Quadrivalent Flu Vaccine Sales Quantity Share by Type (2024-2034)
Table 32. Global Quadrivalent Flu Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Quadrivalent Flu Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Quadrivalent Flu Vaccine Revenue Share by Type (2018-2024)
Table 35. Global Quadrivalent Flu Vaccine Revenue Share by Type (2024-2034)
Table 36. Quadrivalent Flu Vaccine Price by Type (2018-2024) & (USD/Dose)
Table 37. Global Quadrivalent Flu Vaccine Price Forecast by Type (2024-2034) & (USD/Dose)
Table 38. Global Quadrivalent Flu Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 39. Global Quadrivalent Flu Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 40. Global Quadrivalent Flu Vaccine Sales Quantity Share by Application (2018-2024)
Table 41. Global Quadrivalent Flu Vaccine Sales Quantity Share by Application (2024-2034)
Table 42. Global Quadrivalent Flu Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Quadrivalent Flu Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Quadrivalent Flu Vaccine Revenue Share by Application (2018-2024)
Table 45. Global Quadrivalent Flu Vaccine Revenue Share by Application (2024-2034)
Table 46. Quadrivalent Flu Vaccine Price by Application (2018-2024) & (USD/Dose)
Table 47. Global Quadrivalent Flu Vaccine Price Forecast by Application (2024-2034) & (USD/Dose)
Table 48. North America Quadrivalent Flu Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America Quadrivalent Flu Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 50. North America Quadrivalent Flu Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 51. North America Quadrivalent Flu Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 52. North America Quadrivalent Flu Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America Quadrivalent Flu Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Quadrivalent Flu Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 55. North America Quadrivalent Flu Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 56. North America Quadrivalent Flu Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America Quadrivalent Flu Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Quadrivalent Flu Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America Quadrivalent Flu Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America Quadrivalent Flu Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Quadrivalent Flu Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 62. North America Quadrivalent Flu Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 63. Europe Quadrivalent Flu Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 64. Europe Quadrivalent Flu Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe Quadrivalent Flu Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 66. Europe Quadrivalent Flu Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 67. Europe Quadrivalent Flu Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe Quadrivalent Flu Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Quadrivalent Flu Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 70. Europe Quadrivalent Flu Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 71. Europe Quadrivalent Flu Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe Quadrivalent Flu Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Quadrivalent Flu Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe Quadrivalent Flu Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe Quadrivalent Flu Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Quadrivalent Flu Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 77. Europe Quadrivalent Flu Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 78. China Quadrivalent Flu Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 79. China Quadrivalent Flu Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 80. China Quadrivalent Flu Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 81. China Quadrivalent Flu Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 82. China Quadrivalent Flu Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 83. China Quadrivalent Flu Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Quadrivalent Flu Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 85. China Quadrivalent Flu Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 86. China Quadrivalent Flu Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 87. China Quadrivalent Flu Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Quadrivalent Flu Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 89. APAC Quadrivalent Flu Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC Quadrivalent Flu Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 91. APAC Quadrivalent Flu Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 92. APAC Quadrivalent Flu Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC Quadrivalent Flu Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Quadrivalent Flu Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 95. APAC Quadrivalent Flu Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 96. APAC Quadrivalent Flu Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC Quadrivalent Flu Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Quadrivalent Flu Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC Quadrivalent Flu Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC Quadrivalent Flu Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Quadrivalent Flu Vaccine Sales Quantity by Region (2018-2024) & (K Doses)
Table 102. APAC Quadrivalent Flu Vaccine Sales Quantity by Region (2024-2034) & (K Doses)
Table 103. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 104. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 106. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 107. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 110. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 111. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 117. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 118. Sanofi Pasteur Company Information
Table 119. Sanofi Pasteur Description and Overview
Table 120. Sanofi Pasteur Quadrivalent Flu Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 121. Sanofi Pasteur Quadrivalent Flu Vaccine Product and Services
Table 122. Sanofi Pasteur Quadrivalent Flu Vaccine SWOT Analysis
Table 123. Sanofi Pasteur Recent Developments
Table 124. AstraZeneca Company Information
Table 125. AstraZeneca Description and Overview
Table 126. AstraZeneca Quadrivalent Flu Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 127. AstraZeneca Quadrivalent Flu Vaccine Product and Services
Table 128. AstraZeneca Quadrivalent Flu Vaccine SWOT Analysis
Table 129. AstraZeneca Recent Developments
Table 130. CSL Company Information
Table 131. CSL Description and Overview
Table 132. CSL Quadrivalent Flu Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 133. CSL Quadrivalent Flu Vaccine Product and Services
Table 134. CSL Quadrivalent Flu Vaccine SWOT Analysis
Table 135. CSL Recent Developments
Table 136. Abbott Company Information
Table 137. Abbott Description and Overview
Table 138. Abbott Quadrivalent Flu Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 139. Abbott Quadrivalent Flu Vaccine Product and Services
Table 140. Abbott Quadrivalent Flu Vaccine SWOT Analysis
Table 141. Abbott Recent Developments
Table 142. GlaxoSmithKline Company Information
Table 143. GlaxoSmithKline Description and Overview
Table 144. GlaxoSmithKline Quadrivalent Flu Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 145. GlaxoSmithKline Quadrivalent Flu Vaccine Product and Services
Table 146. GlaxoSmithKline Quadrivalent Flu Vaccine SWOT Analysis
Table 147. GlaxoSmithKline Recent Developments
Table 148. Key Raw Materials Lists
Table 149. Raw Materials Key Suppliers Lists
Table 150. Quadrivalent Flu Vaccine Distributors List
Table 151. Quadrivalent Flu Vaccine Customers List
Table 152. Quadrivalent Flu Vaccine Market Trends
Table 153. Quadrivalent Flu Vaccine Market Drivers
Table 154. Quadrivalent Flu Vaccine Market Challenges
Table 155. Quadrivalent Flu Vaccine Market Restraints
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Quadrivalent Flu Vaccine Product Picture
Figure 2. Global Quadrivalent Flu Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Quadrivalent Flu Vaccine Market Share by Type in 2022 & 2034
Figure 4. Intramuscular Injection Product Picture
Figure 5. Nasal Spray Product Picture
Figure 6. Intradermal Shot Product Picture
Figure 7. Global Quadrivalent Flu Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Quadrivalent Flu Vaccine Market Share by Application in 2022 & 2034
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Public Health Agency
Figure 12. Other
Figure 13. Quadrivalent Flu Vaccine Report Years Considered
Figure 14. Global Quadrivalent Flu Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Quadrivalent Flu Vaccine Revenue 2018-2034 (US$ Million)
Figure 16. Global Quadrivalent Flu Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Quadrivalent Flu Vaccine Sales Quantity 2018-2034 (K Doses)
Figure 18. Global Quadrivalent Flu Vaccine Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Quadrivalent Flu Vaccine Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Quadrivalent Flu Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 21. North America Quadrivalent Flu Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Quadrivalent Flu Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 23. Europe Quadrivalent Flu Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Quadrivalent Flu Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 25. China Quadrivalent Flu Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Quadrivalent Flu Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 27. APAC Quadrivalent Flu Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 29. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Quadrivalent Flu Vaccine Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Quadrivalent Flu Vaccine Revenue in 2022
Figure 32. Quadrivalent Flu Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Quadrivalent Flu Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Quadrivalent Flu Vaccine Revenue Market Share by Type (2018-2034)
Figure 35. Global Quadrivalent Flu Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Quadrivalent Flu Vaccine Revenue Market Share by Application (2018-2034)
Figure 37. North America Quadrivalent Flu Vaccine Revenue Market Share by Company in 2022
Figure 38. North America Quadrivalent Flu Vaccine Sales Quantity Market Share by Company in 2022
Figure 39. North America Quadrivalent Flu Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Quadrivalent Flu Vaccine Revenue Market Share by Type (2018-2034)
Figure 41. North America Quadrivalent Flu Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Quadrivalent Flu Vaccine Revenue Market Share by Application (2018-2034)
Figure 43. North America Quadrivalent Flu Vaccine Revenue Share by Country (2018-2034)
Figure 44. North America Quadrivalent Flu Vaccine Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Quadrivalent Flu Vaccine Sales Quantity Market Share by Company in 2022
Figure 48. Europe Quadrivalent Flu Vaccine Revenue Market Share by Company in 2022
Figure 49. Europe Quadrivalent Flu Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Quadrivalent Flu Vaccine Revenue Market Share by Type (2018-2034)
Figure 51. Europe Quadrivalent Flu Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Quadrivalent Flu Vaccine Revenue Market Share by Application (2018-2034)
Figure 53. Europe Quadrivalent Flu Vaccine Revenue Share by Country (2018-2034)
Figure 54. Europe Quadrivalent Flu Vaccine Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 56. France Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 60. China Quadrivalent Flu Vaccine Sales Quantity Market Share by Company in 2022
Figure 61. China Quadrivalent Flu Vaccine Revenue Market Share by Company in 2022
Figure 62. China Quadrivalent Flu Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Quadrivalent Flu Vaccine Revenue Market Share by Type (2018-2034)
Figure 64. China Quadrivalent Flu Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Quadrivalent Flu Vaccine Revenue Market Share by Application (2018-2034)
Figure 66. APAC Quadrivalent Flu Vaccine Sales Quantity Market Share by Company in 2022
Figure 67. APAC Quadrivalent Flu Vaccine Revenue Market Share by Company in 2022
Figure 68. APAC Quadrivalent Flu Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Quadrivalent Flu Vaccine Revenue Market Share by Type (2018-2034)
Figure 70. APAC Quadrivalent Flu Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Quadrivalent Flu Vaccine Revenue Market Share by Application (2018-2034)
Figure 72. APAC Quadrivalent Flu Vaccine Revenue Share by Region (2018-2034)
Figure 73. APAC Quadrivalent Flu Vaccine Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 78. India Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Quadrivalent Flu Vaccine Revenue Share by Country (2018-2034)
Figure 87. Brazil Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Quadrivalent Flu Vaccine Revenue (2018-2034) & (US$ Million)
Figure 92. Quadrivalent Flu Vaccine Value Chain
Figure 93. Quadrivalent Flu Vaccine Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed